Abstract:Background Preeclampsia is a life-threating pregnancy disorder, especially preterm preeclampsia and early-onset preeclampsia, the heterogeneity and complexity of preeclampsia make it difficult to predict risk and develop treatments. Plasma cell-free RNA carries unique information from human tissue and may be useful for noninvasive monitoring of maternal, placental, and fetal dynamics during pregnancy. Objective This study aimed to investigate various RNA biotypes associated with preeclampsia in plasma and develop classifiers to predict preterm preeclampsia and early-onset preeclampsia before diagnosis. Study Design We performed a novel cell-free RNA sequencing method named PALM-Seq to investigate the cell-free RNA characteristics of 715 healthy and 202 preeclampsia pregnancies before symptom onset. We explored changes in the abundance of different RNA biotypes in plasma between healthy and preeclampsia samples and built preterm preeclampsia and early-onset preeclampsia prediction classifiers using machine learning methods. Furthermore, we validated the performance of the classifiers using the external and internal validation cohorts and assessed the area under the curve and positive predictive value. Results We detected 77 differentially expressed genes including mRNA (44%) and miRNA (26%) between healthy and preterm preeclampsia mothers before symptom onset, which could separate preterm preeclampsia from healthy samples and play critical functional roles in preeclampsia physiology. We developed two classifiers for predicting preterm preeclampsia and early-onset preeclampsia before diagnosis based on 13 cell-free RNA signatures and two clinical features (IVF and MAP), respectively. Notably, both classifiers showed enhanced performance compared to the existing methods: the preterm preeclampsia prediction model achieved 81% area under the curve and 68% positive predictive value in an independent validation cohort (preterm PE, n=46; control, n=151); the early-onset preeclampsia prediction model had an area under the curve of 88% and a positive predictive value of 73% in an external validation cohort (early-onset PE, n=28; control, n=234). Furthermore, we demonstrated downregulation of miRNAs may play vital roles in preeclampsia through the upregulation of preeclampsia-relevant target genes. Conclusion Our cohort study presented the first comprehensive transcriptomic landscape of different RNA biotypes in preeclampsia and developed two advanced classifiers with significant clinical importance for preterm preeclampsia and early-onset preeclampsia prediction before symptom onset. We demonstrated for the first time that messenger RNA, microRNA, and long noncoding RNA can simultaneously serve as potential biomarkers of preeclampsia, holding the promise of prevention of preeclampsia in advance. Abnormal cell-free messenger RNA, microRNA and long noncoding RNA molecular changes help to elucidate the pathogenic determinants of preeclampsia, and open new therapeutic windows to effectively reduce pregnancy complications and fetal morbidity.

A blood-based miRNA signature for early non-invasive diagnosis of preeclampsia

Non-invasive preeclampsia prediction using plasma cell-free RNA signatures

Bioinformatics identification and validation of maternal blood biomarkers and immune cell infiltration in preeclampsia: An observational study

Bioinformatics-based Identification of Mirna-, Lncrna-, and Mrna-Associated Cerna Networks and Potential Biomarkers for Preeclampsia.

Lipidomic signatures in patients with early-onset and late-onset Preeclampsia

Identification of novel first-trimester serum biomarkers for early prediction of preeclampsia

Integrated analysis of microRNA and mRNA expression profiles in Preeclampsia

Identification and validation of an angiogenesis-related signature associated with preeclampsia by bioinformatic analysis

Identification of differentially expressed miRNAs in plasma exosomes from patients with early-onset pre-eclampsia using next generation sequencing

Circulating Micrornas As Biomarkers for Diagnosis and Prediction of Preeclampsia: A Systematic Review and Meta-Analysis

miR-31-5p from placental and peripheral blood exosomes is a potential biomarker to diagnose preeclampsia

A cross-sectional analysis of syncytiotrophoblast membrane extracellular vesicles-derived transcriptomic biomarkers in early-onset preeclampsia

Quantification of Preeclampsia-Related Micrornas in Maternal Serum.

Early Detection of Preeclampsia Using Circulating Small non-coding RNA

Early prediction of preeclampsia in pregnancy with cell-free RNA

Uncovering serum placental-related non-coding RNAs as possible biomarkers of preeclampsia risk, onset and severity revealed MALAT-1, miR-363 and miR-17

Elevated Placental microRNA-155 Is a Biomarker of a Preeclamptic Subtype

Serum lncRNAs TUG1, H19, and NEAT1 and their target miR-29b/SLC3A1 axis as possible biomarkers of preeclampsia: Potential clinical insights

Understanding the role of soluble proteins and exosomes in non-invasive urine-based diagnosis of preeclampsia

Detection of early-onset severe preeclampsia by cell-free DNA fragmentome

High Throughput Sequencing Analysis of Exosomal miRNA Expressions in Early-Onset Preeclampsia Patients